Target intelligence / Profile preview

Pseudouridine synthase 1 (PUS1)

Target
PUS1
Molecular classification
Enzyme, RNA-modifying enzyme, Isomerase
01

Overview

Pseudouridine synthase 1 (PUS1) is an enzyme responsible for the post-transcriptional modification of RNA, specifically catalyzing the isomerization of uridine to pseudouridine (Ψ) in tRNA at positions 38 to 40 and, in some species, in mRNA. PUS1 belongs to the pseudouridine synthase family of enzymes, which play ubiquitous roles in RNA processing and gene expression regulation. This modification affects RNA structure and RNA–protein interactions, impacting translation and cellular function. In humans, defects or mutations in PUS1 cause mitochondrial myopathy and sideroblastic anemia (MLASA), underscoring its essential role in mitochondrial function and erythropoiesis. The enzyme acts independently (as a stand-alone synthase) and utilizes specific sequence and structural motifs within target RNAs for substrate recognition and modification[1][2]. No approved drugs are known to modulate PUS1 directly.

Other names
Pseudouridylate synthase 1 homologPP8985MLASA1tRNA pseudouridine synthase 1tRNA pseudouridine(38-40) synthasetRNA pseudouridylate synthase ItRNA-uridine isomerase Imitochondrial myopathy and sideroblastic anemia 1 proteintRNA pseudouridine synthase Amitochondrial tRNA pseudouridine synthase A
02

Mechanism of action

Catalyzes the isomerization of uridine to pseudouridine at specific positions in tRNA and, in some cases, mRNA

03

Biological functions

RNA modificationPost-transcriptional modificationtRNA modificationmRNA modificationpseudouridylation of uridine in RNA
04

Disease associations

Mitochondrial diseaseMitochondrial myopathy and sideroblastic anemia (MLASA)Other
05

Safety considerations

Loss-of-function or mutations are associated with mitochondrial myopathy and sideroblastic anemia (MLASA). There are no direct safety concerns for pharmacological targeting reported.
06

Biomarkers

Mutations in PUS1 as biomarkers for mitochondrial myopathy and sideroblastic anemia

Beyond the preview

Go deeper on Pseudouridine synthase 1 (PUS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pseudouridine synthase 1 (PUS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call